WCLC 2025 - Posters & ePosters-PT1.03.06 Mechanisms of Acquired Resistance to First-Line Amivantamab Plus Lazertinib Vs Osimertinib: Updated Analysis from MARIPOSA

PT1.03.06 Mechanisms of Acquired Resistance to First-Line Amivantamab Plus Lazertinib Vs Osimertinib: Updated Analysis from MARIPOSA

Asset Subtitle

Hidetoshi Hayashi

Meta Tag

Speaker Hidetoshi Hayashi

Topic Tumor Biology – Translational Biology